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Cystic ﬁbrosisSatisfactory treatment of patients with Dravet syndrome (DS) is often difﬁcult. Some success can be achieved
with bromides, but cognitive side effects and disturbed vigilance may limit their use. Here, we present the
case of a successfully treated patient with DS and remarkable features in the course of his disease: additionally
to DS, the patient was diagnosed with cystic ﬁbrosis (CF), another genetic channelopathy. Seizure freedom
could be achieved under treatment with potassium bromide at the age of 15, but at the age of 20, adverse events
made it necessary to stop bromide treatment. After conversion to valproic acid, the patient remained
seizure-free, and neuropsychological tests demonstrated sustained improvement of cognition.
© 2013 The Authors. Published by Elsevier Inc.Open access under CC BY license.1. Introduction
Dravet syndrome (DS, or severemyoclonic epilepsy of infancy (SMEI))
is characterized by temperature-sensitive and pharmacorefractory gener-
alized seizures beginning in the ﬁrst year of life, often evolving to status
epilepticus. Some patients have additional complex partial seizures or
atypical absence seizures. As the disease progresses, cognitive arrest
or deterioration becomes evident in almost all patients in the second
and third years of life after a normal initial psychomotor development.
The long-term cognitive outcome in general is poor, most often with a
low IQ, high mortality rate, and seizure persistence into adulthood [1].
Mutations of the neuronal voltage-gated sodium channel subunit type
1 gene (SCN1A) are the most frequent genetic causes of this syndrome
[2]. Effective treatment is difﬁcult [3], although barbiturates, benzodiaz-
epines, valproic acid, and stiripentol were reported to be of some efﬁca-
cy. Encouraging results have been demonstrated with bromides [4];
however, application is often limited by cognitive side effects and dis-
turbed vigilance.yoclonic epilepsy of infancy;
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king Test; CFTR, cystic ﬁbrosis
butyric acid.
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2.1. Epilepsy and antiepileptic treatment
Wepresent the case of amale patientwho developed, after diagnosis
of cystic ﬁbrosis (CF) at the age of three months, febrile seizures at the
age of one and at the age of three, afebrile seizures, among them gener-
alized tonic-clonic seizures, myoclonic seizures, and atypical absences.
AnMRI scan of the brain at the age of three did not reveal any abnormal-
ity. Given the clinical course, DSwas suspected, and DNA sequence anal-
ysis of the SCN1A gene proved a de novomissensemutation, p.S1231T in
exon 18, which results in an amino acid substitution in the D3S1 seg-
ment [5]. After insufﬁcient sustained effect of antiepileptic treatment
with benzodiazepines, barbiturates, primidone, sultiame, and valproic
acid in varying combinations, the patient received potassium bromide
in addition to valproic acid, primidone, and sultiame, which ﬁnally
led to a cessation of seizures at the age of 7 years except for rare
fever-induced seizures. Subsequently, valproic acid, primidone, and
sultiame could be terminated, and the patient remained seizure-free
under amonotherapywith 2550 mgof potassium bromide daily. Potas-
sium bromide could be gradually reduced to 1700 mg without onset of
seizures. At the age of 17, a further attempt of dose reduction was
performed, and seizures reoccurred when the daily dose was reduced
to 850 mg, but the patient became seizure-free once more with a
daily dose of 2125 mg potassium bromide. At the age of 20, the patient
was still seizure-free, but acne pustulosa and cognitive side effects were
evident and attributed to the treatmentwith potassiumbromide. A con-
version of the antiepileptic therapy frompotassium bromide to valproic
acid was initiated, with an initial daily dose of 150 mg valproic acid
being slowly increased weekly by 150 mg to a ﬁnal daily dose of
1200 mg. Subsequently, bromide was slowly reduced over a period of
eight months, with a reduction of 425 mg every two months. Since
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valproic acid for more than two years, and he is presently 23 years old
(Fig. 1).
2.2. Cognitive development
Psychomotor development gradually deteriorated in the ﬁrst year
after initial status had been normal. At the age of three, the patient
went to a regular nursery school with a special group for mentally
handicapped children followed by diverse supportive schools for
physically and mentally disabled children and subsequent vocational
preparation. After discontinuation of primidone, cognition improved
for a short period; subsequently, the patient was able to learn to
read. Nevertheless, due to the therapy with potassium bromide, cog-
nitive abilities continued to be impaired. Neuropsychological assess-
ment during ongoing bromide therapy included IQ screening,
cognitive speed of processing, attention, verbal, and nonverbal mem-
ory, verbal and nonverbal ﬂuency, construction and orientation, and
the test batteries for the evaluation of attention derived from the
Tests of Attentional Performance (TAP). The testing revealed deﬁcits
in cognitive speed of processing (Trail Making Test, TMT A), tonic
alertness, phasic alertness, divided attention, and selective attention
and verbal ﬂuency with an estimated IQ of 90. A second neuropsycho-
logical assessment after discontinuation of bromide therapy and con-
version to valproic acid conﬁrmed the clinical impression of a
clinically relevant improvement of alertness, divided attention, and
cognitive speed of processing (TMT A) (Fig. 2).
At the age of 23 years, he successfully ﬁnished his training as a
clerk, which he had begun 3 years ago.
2.3. Cystic ﬁbrosis
The patient we report of was diagnosed with cystic ﬁbrosis (CF) in
his ﬁrst year of life, after a homozygous mutation in the cystic ﬁbrosis
transmembrane conductance regulator (CFTR) gene (p.F508 del) was
found. In the following years, the course of CFwas rather uncomplicated.Fig. 1. Schematic illustration of course of disease including medication, types and frequency
the age of 17, a seizure occurred at a dosage of 850 mg/d, this is why the dosage of potassium
remained seizure-free once more. Due to intolerable side effects (cognition and skin), potass
8 months and after a treatment with valproic acid was initiated. The patient remained seizAlthough an exocrine and endocrine pancreatic insufﬁciency emerged,
pulmonary infections were rare.
3. Discussion
Classic clinical features of DS characterize our patient's course of
disease. However, the following two important features make this
case different from other cases:
1. It is remarkable that the patient was not only diagnosed with DS,
but also with CF, both genetic channelopathies conﬁrmed by se-
quence analysis. No concomitant existence of these two genetic
diseases has been described in the literature so far. Yet, a combined
inheritance is difﬁcult to postulate since the CFTR gene is located
on chromosome 7q31.2 [6], whereas the SCN1A gene is located
within a cluster of three sodium channel genes, including SCN2A
and SCN3A, on chromosome 2q24 [7]. Furthermore, the CFTRmuta-
tion is inherited from the patient's parents by an autosomal reces-
sive inheritance, whereas the SCN1A mutation is a de novo
mutation in our patient with a negative parental testing. Of the
cases with DS, 70–80% is caused by mutations of the SCN1A gene,
90% of which occur de novo [8]. Genetic modiﬁers [9] and environ-
mental factors probably contribute to the variable phenotype of
patients with SCN1A mutations.
2. The other remarkable fact is the relatively benign course of both
diseases. Intractable seizures are most commonly a hallmark of
DS. Pharmacological treatment is difﬁcult and ineffective in many
patients [3]. A favorable effect of bromides has been recently
reported [4] whose beneﬁt as antiepileptic pharmacotherapy was
ﬁrst described in 1853. Because of side effects involving skin, gastroin-
testinal tract, and the nervous system, bromideswere, for a long time,
only considered as an adjunctive therapy for children and adolescents
whose generalized tonic-clonic seizures did not respond to conven-
tional antiepileptic drugs [10]. The real mode of action has not yet
been elucidated, though some studies reported that the antiepileptic
mode of action was through γ-aminobutyric acid (GABA), andof seizures, and education. When potassium bromide was reduced for the ﬁrst time at
bromide was subsequently increased up to 2125 mg. Under this treatment, the patient
ium bromide was tapered down again at the age of twenty, this time, over an interval of
ure-free under monotherapy with valproic acid.
Fig. 2. Comparison of neuropsychological assessment during (2009) and after (2011) therapywith potassium bromide. The ﬁgure shows z-values (m = 0, SD = 1), i.e.,−1 b x b 1; 1 is
average, b−1 is below average, and b−2 is far below average. *Difference > 1 SD, **Difference > critical difference.
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postsynaptic membrane [11].
In our patient, potassium bromide was highly effective but led to
severe skin problems that prompted us to discontinue bromide ther-
apy at the age of twenty and to change back to valproic acid, which
had been of limited efﬁcacy before. Subsequently, cognitive function,
i.e., divided attention, alertness, and speed of cognitive processing,
improved. The observation of only moderate mental disability in
adulthood stands in contrast to the previously held notion that DS
had a relatively severe cognitive prognosis.
Whether the mild course of both diseases, DS and CF, is due to the
coexistence of both channelopathies is difﬁcult to say. An interaction
on a genetic basis is rather unlikely as illustrated above. However,
there might be an explanation on a functional level: Epithelial sodium
channels are expressed in alveolar cells and play a crucial role in ion
andﬂuid regulation of the lung. Hyperactivity of these epithelial sodium
channels due to loss of CFTR-mediated inhibition in patients with CF
leads to some of the symptoms present in cystic ﬁbrosis due to
hyperabsorption of sodium resulting in airway dehydration [12].
Having this in mind, an inﬂuence of the mutation in the CFTR gene on
channels other than epithelial sodium channels (for example SCN1A-
encoded sodium channels) might be hypothesized which could then
lead to an amelioration of DS-derived symptoms.
4. Summary
This case report emphasizes the importance of ongoing rational
therapy changes when seizures in patients with epilepsy are treated
unsatisfactorily. Signiﬁcant beneﬁt can be achieved even after years
of drug resistance and when numerous attempts to reach seizure
freedom had failed before. Certainly, this case has many circum-
stances, such as the unusual pathogenesis with two distinct
channelopathies, that make transferability to other epilepsy syn-
dromes difﬁcult. Still, it demonstrates the signiﬁcance of reduction
or discontinuation of medication with severe impact on cognitive
function.Diclosures
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